BOTOX® in the Treatment of Crow's Feet Lines in Japan
Phase 3
Completed
- Conditions
- Lateral Canthus RhytidesCrow's Feet Lines
- Interventions
- Biological: botulinum toxin Type A (24 U)Biological: botulinum toxin Type A (12 U)Other: Normal Saline
- First Posted Date
- 2013-02-22
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Allergan
- Target Recruit Count
- 300
- Registration Number
- NCT01797081
BOTOX® in the Treatment of Upper Facial Lines in Japan
Phase 3
Completed
- Conditions
- Upper Facial RhytidesFrown LinesCrow's Feet LinesGlabellar Lines
- Interventions
- Biological: botulinum toxin Type A (32U)Biological: botulinum toxin Type A (44U)
- First Posted Date
- 2013-02-22
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- Allergan
- Target Recruit Count
- 101
- Registration Number
- NCT01797094
An Extension Study to Assess the Safety, Tolerability, Efficacy, and Treatment Adherence of Dapsone in Acne Vulgaris
Phase 1
Withdrawn
- Conditions
- Acne Vulgaris
- Interventions
- Drug: Dapsone Formulation ADrug: Dapsone Formulation BDrug: Dapsone Formulation CDrug: Dapsone 5% Gel
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2013-02-25
- Lead Sponsor
- Allergan
- Registration Number
- NCT01785836
Safety and Effectiveness of NATRELLE® 410 Highly Cohesive, Anatomically Shaped, Silicone-filled X-Style and L-Style Breast Implants
Not Applicable
Terminated
- Conditions
- Breast AugmentationBreast ReconstructionBreast Implant Revision
- Interventions
- Device: Anatomically shaped, silicone-filled breast implants with low projection or extra-full projection
- First Posted Date
- 2013-02-06
- Last Posted Date
- 2020-06-25
- Lead Sponsor
- Allergan
- Target Recruit Count
- 355
- Registration Number
- NCT01785069
- Locations
- 🇺🇸
Laurence Berkowitz, Campbell, California, United States
🇺🇸Roy Hong, Palo Alto, California, United States
🇺🇸James Namnoum, Atlanta, Georgia, United States
A Study of Quantitative Assessments of Angle Width in Chinese Patients With Open-angle Glaucoma and/or Ocular Hypertension
Terminated
- Conditions
- Open-angle GlaucomaOcular Hypertension
- Interventions
- Other: No Treatment
- First Posted Date
- 2013-02-01
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Allergan
- Target Recruit Count
- 206
- Registration Number
- NCT01781962
A Study of Subject Satisfaction With BOTOX® Cosmetic Treatment in Facial Rhytides
Phase 4
Completed
- Conditions
- Facial Rhytides
- Interventions
- Drug: Normal SalineBiological: onabotulinumtoxinA
- First Posted Date
- 2013-01-29
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- Allergan
- Target Recruit Count
- 125
- Registration Number
- NCT01777620
Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris
Phase 1
Completed
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2013-01-23
- Last Posted Date
- 2019-04-24
- Lead Sponsor
- Allergan
- Target Recruit Count
- 77
- Registration Number
- NCT01773122
A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence
Phase 3
Completed
- Conditions
- Overactive BladderUrinary Incontinence
- Interventions
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2019-04-23
- Lead Sponsor
- Allergan
- Target Recruit Count
- 356
- Registration Number
- NCT01767519
Bimatoprost for the Treatment of Eyebrow Hypotrichosis
Phase 3
Completed
- Conditions
- Eyebrow Hypotrichosis
- Interventions
- Drug: bimatoprost solutionDrug: Vehicle to bimatoprost solution
- First Posted Date
- 2013-01-10
- Last Posted Date
- 2019-04-23
- Lead Sponsor
- Allergan
- Target Recruit Count
- 357
- Registration Number
- NCT01765764
AGN-229666 for the Treatment of Allergic Conjunctivitis
Phase 2
Completed
- Conditions
- Allergic Conjunctivitis
- Interventions
- Drug: AGN-229666Other: vehicle of AGN-229666
- First Posted Date
- 2012-12-21
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Allergan
- Target Recruit Count
- 90
- Registration Number
- NCT01754766
© Copyright 2025. All Rights Reserved by MedPath